U.S. FDA says reviewing Vytorin cholesterol drug

Reuters: "WASHINGTON (Reuters) - U.S. regulators said on Friday they would review whether to take action over Merck & Co Inc's and Schering-Plough Corp's popular cholesterol medicine Vytorin after a study showed it was no better than a generic drug in preventing the build-up of fatty plaque.
The Food and Drug Administration said it had not yet received a final report on the study, called Enhance. The agency's review of Vytorin will take about six months after final results are received, the FDA said."